Russ B. Altman
Academic Appointments
- Professor, Bioengineering
- Professor, Genetics
- Member, Bio-X
- Member, Stanford Cancer Institute
- Professor, Medicine - Biomedical Informatics Research
- Professor (By courtesy), Computer Science
Key Documents
Contact Information
- Academic Offices
Personal Information Email Tel (650) 725-0659 Tel (650) 725-3394Alternate Contact Tiffany Murray Administrative Associate Email Tel Work 650-725-0659
Professional Overview
Administrative Appointments
- Chairman, Department of Bioengineering (2007 - 2012)
- Director, Biomedical Informatics Training Program (2000 - present)
- President, American Society for Clinical Pharmacology and Therapeutics (2013 - 2014)
- President, International Society for Computational Biology (2000 - 2001)
- Member, Biomedical Library and Informatics Research Commitee Study Section (NIH) (2002 - 2005)
Honors and Awards
- Fellow, International Society for Computational Biology (2010)
- Member, Institute of Medicine of the National Academies (2009)
- Fellow, American Institute for Medical and Biological Engineering (2007)
- Fellow, American College of Physicians (1998)
- U.S. Presidential Early Career Award for Scientists & Engineers, NIH (1997)
- Post-Doctoral Fellowship, Howard Hughes Medical Institute (1991)
Professional Education
| AB: | Harvard College, Biochemistry & Molecular Biology (1983) |
| PhD: | Stanford University, Medical Information Sciences (1989) |
| MD: | Stanford University, Medicine (1990) |
Graduate & Fellowship Program Affiliations
Community and International Work
- Attending Physician, Medicine, Menlo Park, CA
Internet Links
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industrial and other commercial partners. It is our policy to disclose payments (exclusive of travel support) from, and/or equity in, companies or other commercial entities to Stanford faculty of $5,000 or more in total value, as well as any equity in a privately held company, when the faculty member also has institutional responsibilities related to his or her interactions with the company. View Full Information
Scientific Focus
Current Research Interests
I am interested in the application of computational technologies to problems in molecular biology of relevance to medicine. In particular, my laboratory focuses on drug response at the molecular level, working in three areas. First, we are building a comprehensive pharmacogenomics knowledge base (http://www.pharmgkb.org/) that provides access to information relating genotype to phenotype (in particular, how variation in genetics leads to variation in response to drugs). We are interested in collaboratively discovering and applying new pharmacogenomics knowledge. Second, we are interested in the analysis of three dimensional biological structures. We have methods for analyzing protein structures to recognize and annotate active sites and binding sites, particularly in the context of interactions with small molecule drugs. We are also interested in physics-based simulation of biological structures to understand how their dynamics impact their function (http://simbios.stanford.edu/). Finally, we are interested in computational methods for analyzing functional genomics information. We use natural language processing techniques for extracting and summarizing information in the literature, chemoinformatics methods for understanding small molecule function, and machine learning & data mining techniques to understand the molecular responses to drugs.
Publications
- Data-driven prediction of drug effects and interactions. Sci Transl Med. 2012; (125): 125ra31
- Discovery and explanation of drug-drug interactions via text mining. Pac Symp Biocomput. 2012: 410-21
- Translational bioinformatics: linking the molecular world to the clinical world. Clin Pharmacol Ther. 2012; (6): 994-1000
- Clinical assessment incorporating a personal genome. Lancet. 2010; (9725): 1525-35
- Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009; (8): 753-64
- Informatics confronts drug-drug interactions. Trends Pharmacol Sci. 2013; (3): 178-84
Help